Compare AU

Compare CURE vs. TBIL

Compare shares and ETFs on the ASX that you can trade on Pearler.

S&P US Biotech

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P US Biotech (CURE) and the VanEck 1-3 Month Us Treasury Bond ETF (TBIL). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

TBIL

Popularity

Low

Low

Pearlers invested

82

4

Median incremental investment

$619.50

$687.74

Median investment frequency

Monthly

Monthly

Median total investment

$1,325.00

$869.22

Average age group

> 35

> 35


Key Summary

CURE

TBIL

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

TBIL.AX was created on 2023-05-16 by VanEck. The fund's investment portfolio concentrates primarily on investment grade fixed income. TBIL.AX invests in a portfolio of US dollar denominated Treasury Bills issued by the US Government with a maturity ranging from 1-3 months with the aim of providing investment returns (before fees and costs) that closely track the returns of the Index

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

United States Treasury Bills (9.18 %)

United States Treasury Bills (8.47 %)

United States Treasury Bills (8.46 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.22 %


Key Summary

CURE

TBIL

Issuer

Global X

VanEck

Tracking index

S&P Biotechnology Select Industry

Bloomberg 1-3 Month U.S. Treasury Bill Index - Benchmark TR Gross

Asset class

ETF

ETF

Management fee

0.45 %

0.22 %

Price

$50.00

$52.68

Size

$36.301 million

N/A

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

1.51 %

Market

ASX

ASX

First listed date

12/11/2018

17/05/2023

Purchase fee

$6.50

$6.50


Community Stats

CURE

TBIL

Popularity

Low

Low

Pearlers invested

82

4

Median incremental investment

$619.50

$687.74

Median investment frequency

Monthly

Monthly

Median total investment

$1,325.00

$869.22

Average age group

> 35

> 35


Pros and Cons

CURE

TBIL

Pros

  • Higher exposure to US market

  • Higher distribution yield

  • Lower management fee

  • Higher price growth

Cons

  • Higher management fee

  • Lower price growth

  • Lower exposure to US market

  • Lower distribution yield

CURE

TBIL

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home